Kasteler, Rahel; Lichtensteiger, Christa; Schindera, Christina; Ansari, Marc; Kuehni, Claudia E. (2021). Validation of questionnaire-reported chest wall abnormalities with a telephone interview in Swiss childhood cancer survivors. BMC cancer, 21(1), p. 787. BioMed Central 10.1186/s12885-021-08425-z
|
Text
Kasteler_BMCCancer_2021.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (458kB) | Preview |
|
|
Text
Kasteler_BMCCancer_2021_suppl1.pdf - Supplemental Material Available under License Creative Commons: Attribution (CC-BY). Download (314kB) | Preview |
|
|
Text (Fragebogen)
Kasteler_BMCCancer_2021_suppl2_Fragebogen.pdf - Supplemental Material Available under License Creative Commons: Attribution (CC-BY). Download (233kB) | Preview |
|
|
Text (Questionnaire)
Kasteler_BMCCancer_2021_suppl3_Questionnaire.pdf - Supplemental Material Available under License Creative Commons: Attribution (CC-BY). Download (236kB) | Preview |
BACKGROUND
Chest wall abnormalities are a poorly studied complication after treatment for childhood cancer. Chest wall abnormalities are not well-described in the literature, and little is known on the impact on daily life of survivors.
METHODS
We investigated prevalence and risk factors of chest wall abnormalities in childhood cancer survivors in a nationwide, population-based cohort study (Swiss Childhood Cancer Survivor Study) with a questionnaire survey. We then interviewed a nested sample of survivors to validate types of chest wall abnormalities and understand their impact on the daily life of survivors.
RESULTS
Forty-eight of 2382 (95%CI 2-3%) survivors reported a chest wall abnormality. Risk factors were older age at cancer diagnosis (16-20 years; OR 2.5, 95%CI 1.0-6.1), lymphoma (OR 3.8, 95%CI 1.2-11.4), and central nervous system tumors (OR 9.5, 95%CI 3.0-30.1) as underlying disease, and treatment with thoracic radiotherapy (OR 2.0, 95%CI 1.0-4.2), surgery to the chest (OR 4.5, 95%CI 1.8-11.5), or chemotherapy (OR 2.9, 95%CI 1.0-8.1). The nature of the chest wall abnormalities varied and included thoracic wall deformities (30%), deformations of the spine (5%) or both (55%), and scars (10%). Chest wall abnormalities affected daily life in two thirds (13/20) of those who reported these problems and necessitated medical attention for 15 (75%) survivors.
CONCLUSION
It is important that, during follow-up care, physicians pay attention to chest wall abnormalities, which are rare late effects of cancer treatment, but can considerably affect the well-being of cancer survivors.
Actions (login required)
 |
Edit item |